WallStSmart

Axsome Therapeutics Inc (AXSM)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Axsome Therapeutics Inc generates 5% more annual revenue ($638.50M vs $606.42M). INSM leads profitability with a -2.1% profit margin vs -28.7%. INSM earns a higher WallStSmart Score of 39/100 (F).

AXSM

Avoid

30

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 4.0
Piotroski: 4/9Altman Z: -2.07

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AXSM1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
65.0%10/10

Revenue surging 65.0% year-over-year

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

AXSM4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
93.0x2/10

Trading at 93.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Free Cash FlowQuality
$-19.00M2/10

Negative free cash flow — burning cash

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : AXSM

The strongest argument for AXSM centers on Revenue Growth. Revenue growth of 65.0% demonstrates continued momentum.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : AXSM

The primary concerns for AXSM are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 2.96 is elevated, increasing financial risk.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

AXSM profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

AXSM is growing revenue faster at 65.0% — sustainability is the question.

AXSM generates stronger free cash flow (-19M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Axsome Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.

Visit Website →

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?